Jeronimo
Martinez Garcia
Asociado Ciencias de la Salud
Hospital Vall d'Hebron
Barcelona, EspañaPublicacions en col·laboració amb investigadors/es de Hospital Vall d'Hebron (6)
2024
-
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
The Lancet, Vol. 403, Núm. 10421, pp. 31-43
-
Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study
Gynecologic Oncology, Vol. 185, pp. 202-211
2023
-
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 30, pp. 4768-4778
-
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer
Journal of Clinical Oncology
2017
-
Performance of the clinical index of stable febrile neutropenia (CISNE) in different types of infections and tumors
Clinical and Translational Oncology, Vol. 19, Núm. 3, pp. 386-395
2016
-
A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia
British Journal of Cancer, Vol. 114, Núm. 11, pp. 1191-1198